Table 1.
Demographics | Value | % |
---|---|---|
Age | ||
Mean | 68 years | |
Median | 70 years | |
Range | 33–91 years | |
Gender | ||
Female | 83 | 42 |
Male | 117 | 58 |
Rectal carcinoma | 71 | 35 |
Rectum 0–5 cm | 16 | |
Rectum 5–10 cm | 34 | |
Rectum 10–15 cm | 21 | |
Colon carcinoma | 129 | 65 |
Resection of the primary tumor | 199 | 99 |
Neoadjuvant treatment | ||
Neoadjuvant chemoradiation rectal carcinoma | 33a | |
Neoadjuvant radiotherapy (5×5Gy) rect. ca | 7a | |
Chemotherapy | 1b | |
Urgency | ||
Elective procedure | 164 | 81 |
Urgent and acute procedures | 36 | 19 |
In-hospital mortality | ||
Elective procedures | 4 | 2 |
Urgent en acute procedures | 4 | 11 |
AJCC stage based on pTNM (2002) | ||
Stage 0c | 6 | 3 |
Stage I | 22 | 11 |
Stage II | 56 | 28 |
Stage III | 56 | 28 |
Stage IVd | 60 | 30 |
Follow-up | ||
Mean | 19 months | |
Median | 19 months | |
Range | 12–30 months |
aNeoadjuvant treatment was given to patients with rectal carcinoma cT3-4N1-2 on MRI, located at 0–10 cm (lowest border of the tumor) from the anal verge. From 40 patients who received neoadjuvant radiation or chemoradiation, 11 had indeterminate lesions on chest CT
bThis patient initially received palliative chemotherapy for asymptomatic disease and incurable liver metastases. This strategy was changed when the primary tumor became symptomatic
cComplete regression after neoadjuvant chemoradiation for rectal carcinoma (cT3-4N1-2)
dIn this table, metastases that were suspected on staging CT and confirmed during follow-up were classified as AJCC stage IV. Suspected metastases that were resected and histologically benign were classified as stage II or III disease. This overview therefore represents the actual oncological status in the study cohort